Ivermectin in the treatment of COVID-19-friend or foe?

被引:0
|
作者
Schellack, N. [1 ]
Padayachee, N. [2 ]
Schellack, G. [3 ]
机构
[1] Univ Pretoria, Pretoria, South Africa
[2] Univ Witwatersrand, Clin Pharm, Dept Pharm & Pharmacol, Johannesburg, South Africa
[3] Clin Res & Appl Pharmacol, Cape Town, South Africa
关键词
COVID-19; SARS-CoV-2; ivermectin; avermectin; macrocyclic lactone; endectocide; ADVERSE-REACTIONS; SAFETY; PHARMACOKINETICS; PROTEIN; DENGUE; DRUG;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The global number of deaths due to COVID-19 is almost at the two million mark, with over 35 000 deaths in South Africa. Although there are hopes of a safe and effective vaccination programme, the increasing number of COVID-19 cases in the country is putting a significant strain on the healthcare system. Ivermectin, an antiparasitic drug, has been widely published on social media platforms and news outlets as a so-called miracle drug for the treatment of COVID-19. Ivermectin is not registered in SA as a drug for human use, but rather as a veterinary and agricultural product. Currently, from a small number of randomised controlled trials (RCTs), there does seem to be a signal of evidence for the use of ivermectin in the management of COVID-19. Pharmacists must, however, remain cognisant of their ethical responsibilities as well as the applicable regulations that prohibit the procurement and dispensing of any unregistered medicine.
引用
收藏
页码:11 / +
页数:5
相关论文
共 50 条
  • [31] COVID-19 vaccines and blood glucose control: Friend or foe?
    Vena, Walter
    Pigni, Stella
    Betella, Nazarena
    Navarra, Annalisa
    Mirani, Marco
    Mazziotti, Gherardo
    Lania, Andrea G.
    Bossi, Antonio C.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [32] The Use of Ivermectin in the Treatment of COVID-19
    Shukla, Ajay Kumar
    Misra, Saurav
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (06) : 1554 - 1554
  • [33] Ivermectin: potential candidate for the treatment of Covid 19
    Gupta, Dhyuti
    Sahoo, Ajaya Kumar
    Singh, Alok
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2020, 24 (04): : 369 - 371
  • [34] IP-10 and complement activation as friend or foe in COVID-19
    Bunprakob, Saowalak
    Hemachudha, Pasin
    Ruchisrisarod, Chanida
    Supharatpariyakorn, Thirawat
    Hemachudha, Thiravat
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [35] The Use of Ivermectin in the Treatment of COVID-19
    Ajay Kumar Shukla
    Saurav Misra
    [J]. Journal of General Internal Medicine, 2023, 38 : 1554 - 1554
  • [36] Ivermectin as a potential treatment for COVID-19?
    Chosidow, Olivier
    Bernigaud, Charlotte
    Guillemot, Didier
    Giraudeau, Bruno
    Lespine, Anne
    Changeux, Jean-Pierre
    Bourhy, Herve
    Lecuit, Marc
    Amoura, Zahir
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (06):
  • [37] Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Sieiro Santos, Cristiana
    Casas Fernandez, Xenia
    Moriano Morales, Clara
    Diez Alvarez, Elvira
    Alvarez Castro, Carolina
    Lopez Robles, Alejandra
    Perez Sandoval, Trinidad
    [J]. RMD OPEN, 2021, 7 (01):
  • [38] Epistemic responsibilities in the COVID-19 pandemic: Is a digital infosphere a friend or a foe
    Curkovic, Marko
    Kosec, Andro
    Bedekovic, Marina Roje
    Bedekovic, Vladimir
    [J]. JOURNAL OF BIOMEDICAL INFORMATICS, 2021, 115
  • [39] Toll-like receptor 4 in COVID-19: friend or foe?
    Mukherjee, Suprabhat
    [J]. FUTURE VIROLOGY, 2022, 17 (07) : 415 - 417
  • [40] BIOLOGIC AGENTS FOR RHEUMATIC DISEASES IN THE COVID-19 OUTBREAK: FRIEND OR FOE?
    Santos, Cristiana S.
    Moriano Morales, Claim
    Diez Alvarez, Elvira
    Alvarez Castro, Caroling
    Lopez Robles, Alejandra
    Perez Sandoval, Trinidad
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S3 - S4